Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
10 - Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
Published online by Cambridge University Press: 05 March 2016
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 79 - 85Publisher: Cambridge University PressPrint publication year: 2016
References
Mascarenhas, J, Mughal, T, Verstovsek, S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012;19:4399–413.CrossRefGoogle ScholarPubMed
Kralovics, R, Passamonti, F, Buser, A, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.CrossRefGoogle ScholarPubMed
Levine, RL, Wadleigh, M, Cools, J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr;7(4):387–97. PubMed PMID: 15837627.CrossRefGoogle ScholarPubMed
Baxter, EJ, Scott, LM, Campbell, PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet. 2005;365(9464):1054–61.CrossRefGoogle ScholarPubMed
James, C, Ugo, V, Couedic, J-PL, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.CrossRefGoogle ScholarPubMed
Ward, AC, Touw, I, Yoshimura, A. The JAK-STAT pathway in normal and perturbed hematopoiesis. Blood. 2000;95(1):19–29.CrossRefGoogle ScholarPubMed
Verstovsek, S, Kantarjian, H, Mesa, R, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117–27.CrossRefGoogle ScholarPubMed
Verstovsek, S, Kantarjian, HM, Estrov, Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012;120(6):1202–9. PubMed PMID: 22718840.CrossRefGoogle ScholarPubMed
Verstovsek, S, Mesa, R, Gotlib, J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.CrossRefGoogle ScholarPubMed
Harrison, C, Kiladjian, J, Al-Ali, H, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–98.CrossRefGoogle ScholarPubMed
Cervantes, F, Dupriez, B, Pereira, A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–901. PubMed PMID: 18988864.CrossRefGoogle Scholar
Verstovsek, S, Mesa, RA, Gotlib, J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865–71.CrossRefGoogle ScholarPubMed
Cervantes, F, Vannucchi, AM, Kiladjian, JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047–53. PubMed PMID: 24174625.CrossRefGoogle ScholarPubMed
Vannucchi, AM, Hagop, K, Kiladjian, J-J, et al. A pooled overall survival analysis of the COMFORT studies: 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Blood. 2013;45;122(21):2820.Google Scholar
Passamonti, F, Maffioli, M, Cervantes, F, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014;123(12):1833–5.CrossRefGoogle ScholarPubMed
Kvasnicka, H, Thiele, J, Bueso-Ramos, C, et al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy. Blood. 2013;122(21):4055.CrossRefGoogle Scholar
Vannucchi, AM, Passamonti, F, Al-Ali, HK, et al. Reductions in JAK2 V617F allele burden with ruxolitinib treatment in comfort-ii, a phase 3 study comparing the safety and efficacy of ruxolitinib with best available therapy (BAT). ASH Annual Meeting Abstracts. 2012 November 16, 2012;120(21):802.Google Scholar
Geyer, H, Cannon, K, Knight, E, et al. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval. Leuk Lymphoma. 2014;55(1):195–7. PubMed PMID: 23647081.CrossRefGoogle ScholarPubMed
Verstovsek, S, Gotlib, J, Gupta, V, et al. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther. 2013;7:13–21. PubMed PMID: 24368888. Pubmed Central PMCID: 3869911.CrossRefGoogle ScholarPubMed
Talpaz, M, Paquette, R, Afrin, L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013;6:81–90.CrossRefGoogle ScholarPubMed
Tefferi, A, Pardanani, A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86(12):1188–91.CrossRefGoogle ScholarPubMed